EP Patent

EP0436492A2 — R-Enantiomer of N-propargyl-1-aminoindan, its preparation and pharmaceutical compositions containing it

Assigned to Teva Pharmaceutical Industries Ltd · Expires 1991-07-10 · 35y expired

What this patent protects

R(+)-N-propargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and …

USPTO Abstract

R(+)-N-propargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.

Drugs covered by this patent

Patent Metadata

Patent number
EP0436492A2
Jurisdiction
EP
Classification
Expires
1991-07-10
Drug substance claim
No
Drug product claim
No
Assignee
Teva Pharmaceutical Industries Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.